effects of glucagon on the heart and circulatio

Phase 1

• Conditions: Glucagon-induced changes in heart rate, blood pressure, cardiac output. and metabolic effects; Therapeutic area: Body processes [G] - Physical Phenomena [G01]

• Registration Number: EUCTR2019-002638-36-DK
• Lead Sponsor: Bispebjerg Hospital, University of Copenhagen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-06-27
• Last Update Posted: 10 August 2020

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: Male
• Target Recruitment: 8

Inclusion Criteria

Eligible participants are males 18 to 40 years of age determined to be
healthy by physical examination, medical history and routine laboratory
tests (blood and urine) - i.e. normal levels of sodium, potassium,
calcium, liver function, kidney function, hematological parameters,
albumin, HbA1c, lipid levels.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 8
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Routine laboratory tests outside normal ranges
•Hypertension
•Second and third degree atrioventricular conduction block
•Resting Systolic blood pressure >140 or <100 mmHg
•Resting heart rate < 45 beats per minute (bpm)
•Sick sinus syndrome
•Pheochromocytoma
•Asthma
•Chronic obstructive pulmonary disease
•Abnormal body mass index
•Claudicatio intermittens
•Raynaud syndrome
•Latex allergy
•Any contraindications to glucagon

Any other previous or existing metabolic, heart or lung disease

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified